Search results for "Drug Interaction"

showing 10 items of 246 documents

On cosmetically treated hair — aspects and pitfalls of interpretation

1997

Popular hair cosmetic treatments like bleaching or permanent waving were found to affect the stability of incorporated drugs and to cause alterations of the fibers at an ultrastructural level. This may result in a partial or complete loss of drug substances, depending on the particular drug molecule and on its concentration prior to the cosmetic treatment. Moreover, from literature, there is some evidence that drug molecules are not only incorporated into the growing fiber by passive diffusion from blood into the matrix cells and melanocytes, but that the substances enter the hair also via perspiration such as sweat and sebum. Since permed and bleached hair shows an enhanced sorption capaci…

NarcoticsDrugmedicine.medical_specialtymedia_common.quotation_subjectHair PreparationsDrug moleculeGas Chromatography-Mass SpectrometryPathology and Forensic MedicineSWEATchemistry.chemical_compoundInternal medicinemedicineHumansDrug InteractionsPerspirationSweatmedia_commonintegumentary systembiologyChemistryHair analysisCodeinebiology.organism_classificationSurgerySebumSubstance Abuse DetectionEndocrinologyBenzoylecgoninesense organsmedicine.symptomLawCabelloHairmedicine.drugForensic Science International
researchProduct

Modulation of drug transport by selected flavonoids: Involvement of P-gp and OCT?

2004

Flavonoids, as a common component of daily nutrition, are a possible source of interference with absorption processes, due to modulation of transporting proteins. In this study, the influence of selected flavonoids (quercetin, isoquercitrin, spiraeoside, rutin, kaempferol, naringenin, naringin, and kaempferol) on the transport of the P-gp substrate [3H]talinolol across Caco-2 cell monolayers was investigated. To elucidate the mechanism behind the interaction observed in this system the potency of the flavonoids to replace [3H]talinolol from its P-gp binding site as well as their activity to inhibit OCT2-mediated [14C]TEA uptake into LLC-PK(1) cells were measured, as P-gp and OCT have been s…

NaringeninCell Membrane PermeabilityOrganic Cation Transport ProteinsFlavonoidPharmaceutical ScienceBinding CompetitivePropanolaminesFood-Drug InteractionsRadioligand Assaychemistry.chemical_compoundRutinHumansheterocyclic compoundsATP Binding Cassette Transporter Subfamily B Member 1NaringinFlavonoidschemistry.chemical_classificationHesperetinfood and beveragesBiological TransportchemistryBiochemistryCaco-2 CellsKaempferolQuercetinTalinololEuropean Journal of Pharmaceutical Sciences
researchProduct

Caki-1 cells as a model system for the interaction of renally secreted drugs with OCT3.

2008

<i>Background/Aims:</i> Organic cation transporters (OCT) in the proximal tubules (PTs) participate in the renal secretion of several therapeutic agents. The exact role of OCT3 in renal secretion remains undetermined, partially due to the lack of an appropriate in vitro model system. The current work introduces the PT representative cell line, Caki-1, as a model system for studying the involvement of OCT3 in renal secretion. <i>Methods:</i> Caki-1 cells were characterized for OCT3 expression via real-time RT-PCR and immunocytochemical staining techniques. Uptake kinetics of OCT3 in Caki-1 cells was determined using prototypical substrates and inhibitors. Inhibition o…

Nephrologymedicine.medical_specialty1-Methyl-4-phenylpyridiniumOrganic Cation Transport ProteinsPhysiologyCell SurvivalUrinary systemmacromolecular substancesPharmacologyurologic and male genital diseasesCell LineXenobioticsKidney Tubules ProximalPhysiology (medical)Internal medicinemedicineHumansSecretionRNA MessengerKidneyOrganic cation transport proteinsbiologyDose-Response Relationship Drugbusiness.industryOrganic Cation Transporter 1Organic Cation Transporter 2Epithelial CellsGeneral MedicineDrug interactionmedicine.diseaseImmunohistochemistryQuaternary Ammonium CompoundsKineticsEndocrinologymedicine.anatomical_structureNephrologyRenal physiologybiology.proteinbusinessKidney diseaseNephron. Physiology
researchProduct

Pharmacological and biochemical study on the effects of selective phosphodiesterase inhibitors on human term myometrium

1999

This study was aimed at evaluating the in vitro effects of phosphodiesterase inhibitors and beta2-adrenoceptor agonists on spontaneous contractions of human term myometrium. Rolipram, RP 73401 (3-cyclopentyloxy-N-(3,5(-dichloro-4-pyridil)-4-methoxybenzamide) and Ro 20-1724 (1-4-(3-butoxy-4-methoxybenzyl)-2-imidozolidinone) (phosphodiesterase 4 inhibitors) inhibited spontaneous myometrial contractions (Emax approximately 100%; pD2 of 6.80+/-0.28, 6.84+/-0.32 and 6.31+/-0.03, respectively). Salbutamol and formoterol were less effective (Emax=40+/-6% and 35+/-12%, respectively) than phosphodiesterase 4 inhibitors to reduce myometrial contractility. Inhibitors of phosphodiesterase 3 (milrinone …

Nitroprussidemedicine.medical_specialtyTocolytic agentPhosphodiesterase InhibitorsSiguazodanPhosphodiesterase 3In Vitro Techniqueschemistry.chemical_compoundPregnancyInternal medicinemedicineHumansDrug InteractionsRolipramPharmacologyChromatographyDose-Response Relationship DrugPhosphoric Diester HydrolasesPhosphodiesteraseGeneral MedicineAdrenergic beta-AgonistsIsoenzymesEndocrinologychemistryMyometriumMilrinoneFemaleSodium nitroprussideZaprinastmedicine.drugNaunyn-Schmiedeberg's Archives of Pharmacology
researchProduct

Designing robust immediate release tablet formulations avoiding food effects for BCS class 3 drugs

2019

Abstract Food induced viscosity in the gastrointestinal tract is reported to reduce the bioavailability of tablets containing BCS class 3 drugs, mainly by retarding their disintegration and dissolution of the active pharmaceutical ingredient. The role of formulation factors in minimizing this negative food effect is largely unknown. Combinations of disintegrants were studied together with soluble and insoluble fillers and trospium chloride as model drug substance. Different batches of tablets were compressed at 10 kN and 30 kN, by incorporating different combinations of croscarmellose sodium (CSS), cross-linked (CPD) and sodium starch glycolate (SSG) at low level i.e, 2% + 2% and high level…

NortropanesChemistry PharmaceuticalDrug CompoundingPharmaceutical Science02 engineering and technologyBenzilates030226 pharmacology & pharmacyExcipientsFood-Drug Interactions03 medical and health sciencesViscositychemistry.chemical_compound0302 clinical medicineFood scienceSolubilityLactoseDissolutionActive ingredientCroscarmellose sodiumViscosityChemistryGeneral Medicine021001 nanoscience & nanotechnologyBioavailabilityMicrocrystalline celluloseDrug LiberationSolubilityDrug Design0210 nano-technologyTabletsBiotechnologyEuropean Journal of Pharmaceutics and Biopharmaceutics
researchProduct

Cytotoxicity, Genotoxicity and Disturbance of Cell Cycle in HepG2 Cells Exposed to OTA and BEA: Single and Combined Actions

2019

Mycotoxins are produced by a number of fungal genera spp., for example, Aspergillus, Penicillium, Alternaria, Fusarium, and Claviceps. Beauvericin (BEA) and Ochratoxin A (OTA) are present in various cereal crops and processed grains. This goal of this study was to determine their combination effect in HepG2 cells, presented for the first time. In this study, the type of interaction among BEA and OTA through an isobologram method, cell cycle disturbance by flow cytometry, and genotoxic potential by in vitro micronucleus (MN) assay following the TG 487 (OECD, 2016) of BEA and OTA individually and combined in HepG2 cells are presented. Cytotoxic concentration ranges studied by the MTT assay ov…

Ochratoxin AFusariumCell SurvivalHealth Toxicology and Mutagenesislcsh:MedicineToxicologymedicine.disease_causeArticle03 medical and health scienceschemistry.chemical_compound0404 agricultural biotechnologyDepsipeptidesmedicineHumansDrug InteractionsMTT assayFood scienceMycotoxinHepG2 cells030304 developmental biology0303 health sciencesMicronucleus Testsbiologybeauvericingenotoxicitylcsh:Rfood and beveragesHep G2 Cells04 agricultural and veterinary sciencesbiology.organism_classificationOchratoxins040401 food scienceBeauvericinmixtureschemistryPenicilliumcell cycleMicronucleusochratoxin AGenotoxicityDNA DamageToxins
researchProduct

Fluvoxamine but not sertraline inhibits the metabolism of olanzapine: evidence from a therapeutic drug monitoring service.

2001

Therapeutic drug monitoring data of the new atypical neuroleptic drug olanzapine were used to study interactions with the selective serotonin reuptake inhibitors fluvoxamine and sertraline. The distribution of the ratio of concentration/daily dose (C/D; ng/mL per mg/d) of olanzapine was compared in three groups: patients treated with olanzapine (n = 134), patients treated with olanzapine plus fluvoxamine (n = 10) concomitantly, and patients treated with olanzapine plus sertraline (n = 21) concomitantly. No significant difference was seen between the olanzapine and the olanzapine plus sertraline groups. Patients receiving fluvoxamine in addition to olanzapine had C/D ratios that were in the …

OlanzapineAdultMaleFluvoxaminePharmacologyBenzodiazepinesPharmacokineticsCytochrome P-450 Enzyme SystemSertralineMedicineHumansPharmacology (medical)Drug InteractionsAdverse effectChromatography High Pressure LiquidAgedPharmacologySertralineDepressive Disordermedicine.diagnostic_testbusiness.industryPirenzepineDrug interactionMiddle AgedLiverTherapeutic drug monitoringFluvoxamineOlanzapineAntidepressive Agents Second-GenerationFemaleDrug MonitoringbusinessReuptake inhibitorSelective Serotonin Reuptake Inhibitorsmedicine.drugTherapeutic drug monitoring
researchProduct

Fluvoxamine augmentation of olanzapine in chronic schizophrenia: pharmacokinetic interactions and clinical effects.

2002

Olanzapine is a substrate of the cytochrome P450 enzyme (CYP) 1A2. In this study, pharmacokinetic interactions and clinical effects of adding the CYP1A2 inhibitor fluvoxamine to steady-state olanzapine was examined in patients suffering from schizophrenia. Eight patients had been treated for at least 3 months with 10 to 20 mg/day olanzapine. Fluvoxamine (100 mg/day) was added (week 0) to the olanzapine treatment and continued for 8 weeks. Concentrations of olanzapine and its metabolite N-desmethylolanzapine and of fluvoxamine were analyzed at weeks 0, 1, 4, and 8. Addition of fluvoxamine resulted in a 12% to 112% (0.01) increase of olanzapine from 31 +/- SD 15 ng/mL (week 0) to 56 +/- 31 ng…

OlanzapineAdultMaleTime FactorsCombination therapyFluvoxaminePharmacologyBenzodiazepinesPharmacokineticsmedicineHumansPharmacology (medical)Drug InteractionsProspective Studiesmedicine.diagnostic_testbusiness.industryDopamine antagonistPirenzepineDrug interactionMiddle AgedPsychiatry and Mental healthTherapeutic drug monitoringChemotherapy AdjuvantFluvoxamineOlanzapineChronic DiseaseSchizophreniaFemalebusinessReuptake inhibitorSelective Serotonin Reuptake Inhibitorsmedicine.drugFollow-Up StudiesJournal of clinical psychopharmacology
researchProduct

Glycine Receptors Mediate Excitation of Subplate Neurons in Neonatal Rat Cerebral Cortex

2008

The development of the cerebral cortex depends on genetic factors and early electrical activity patterns that form immature neuronal networks. Subplate neurons (SPn) are involved in the construction of thalamocortical innervation, generation of oscillatory network activity, and in the proper formation of the cortical columnar architecture. Because glycine receptors play an important role during early corticogenesis, we analyzed the functional consequences of glycine receptor activation in visually identified SPn in neocortical slices from postnatal day 0 (P0) to P4 rats using whole cell and perforated patch-clamp recordings. In all SPn the glycinergic agonists glycine, β-alanine, and taurin…

Patch-Clamp TechniquesTaurinePhysiologyGlycineIn Vitro TechniquesBiologyMembrane PotentialsReceptors GlycineSubplatemedicineAnimalsDrug InteractionsGlycine receptorgamma-Aminobutyric AcidCerebral CortexNeuronsNeonatal ratDose-Response Relationship DrugGeneral NeuroscienceExcitatory Postsynaptic PotentialsDose-Response Relationship RadiationGlycine AgentsStrychnineElectric StimulationRatsmedicine.anatomical_structureAnimals NewbornCerebral cortexbeta-AlanineCalciumNeuroscienceJournal of Neurophysiology
researchProduct

Effects of bupivacaine on human erythrocytes submitted to stress and evidence for an interaction between bupivacaine and flumazenil

1999

Aims To examine the effects of bupivacaine on erythrocytes submitted to an oxidative stress (AAPH) and to provide evidence for an in vitro interaction between bupivacaine and flumazenil. Methods Human erythrocytes were studied with or without AAPH in the presence of different concentrations of bupivacaine (0.15, 0.3, 0.9 and 1.8 mmol l−1 ), or flumazenil (0.16 mmol l−1 ) and with the association of flumazenil and two doses of bupivacaine (0.15 and 0.3 mmol l−1 ). Potassium efflux was measured by flame photometry at t0, and every 30 min for 2 h. Results In the absence of AAPH, extracellular potassium remained unchanged. Oxidative stress induced a significant increase in extracellular potassi…

PharmacologyBupivacaineChemistryLocal anestheticmedicine.drug_classPotassiumchemistry.chemical_elementPharmacologyDrug interactionmedicine.disease_causeRed blood cellmedicine.anatomical_structureFlumazenilmedicinePharmacology (medical)IncubationOxidative stressmedicine.drugBritish Journal of Clinical Pharmacology
researchProduct